Increase the potency
of your mRNA with
CleanCap M6 analog

Obtain 30%+ higher protein expression

CleanCap® Reagent M6

CleanCap Reagent M6 [CleanCap m6AG (3’ OMe)], is designed for the co-transcriptional capping of mRNA to produce an mRNA with base modified Cap 1.

 

Using the same 5’ AG initiation sequence as CleanCap AG and CleanCap AG (3’OMe), the CleanCap M6 analog has the addition of a methyl group on position 6 of the first adenosine (m6A) which may further increase protein expression. It has been hypothesized the m6A modification adjacent to the 7-methylguanosine cap can positively influence mRNA stability by preventing enzyme-mediated decapping (Mauer et al. 2017)

CleanCap M6 Reagent structure

CleanCap M6 outperforms
previous analogs 

In internal comparison studies, CleanCap M6 promoted higher protein translation (FLuc) than observed with other CleanCap analogs, driving an increase in the potency of your mRNA drug substance. 

Performance of FLuc mRNA in and LNP-Formulated, tail vein delivered mouse model. 1 mg/kg dose per group. Luciferase activity, as photons per second, is measured after luciferin injection. The difference between groups is cap analog structure. All other variables are controlled.
Performance of FLuc mRNA in and LNP-Formulated, tail vein delivered mouse model. 1 mg/kg dose per group. Luciferase activity, as photons per second, is measured after luciferin injection. The difference between groups is cap analog structure. All other variables are controlled.

More potent mRNA than enzymatically capped constructs

When compared to enzymatic capping strategies, the CleanCap M6 analog demonstrated significantly higher protein translation (FLuc), resulting in higher manufacturing yields.

CleanCap M6 - Results post FLuc mRNA-LNP Infusion
Hours post FLuc mRNA-LNP infusion.
*p<0.001, two-tailed T test.
Error bars are standard error of mean. n=9/group

Access the #1 capping strategy for efficient mRNA translation

Note

CleanCap M6 can be used in conjunction with wildtype bases or TriLink’s catalog of modified NTPs, such as N1-Methylpseudouridine-5’-Triphosphate (N-1081), Pseudouridine- 5’-Triphosphate (N-1019), and 5-Methoxyuridine-5’-Triphosphate (N-1093)

Any questions? 

If you’d like more information, or have any questions about your mRNA projects and needs, get in contact with us, we’ll be pleased to suggest the best solutions to facilitate your research.

Ask our experts